NEO Performance Materials - Part 5: The Valuation

We know what the company does. We know why it's defensible. One question left: what is it worth?

Previously: Part 4 mapped three compounding layers of defensibility: customer qualification lock-in spanning 18 to 36 months per platform across 7-to-12-year vehicle production cycles, 40 years of Magnequench process knowledge that cannot be acquired by buying equipment or licensing technology, and a geographic position inside the EU's Critical Raw Materials Act framework that has regulatory momentum and government capital structurally oriented toward expanding exactly the kind of asset Neo has already built. The moat exists. It compounds. And every year the market fails to price it is a year the lock-in deepens. If you haven't read Part 4, I'd start there.

---

What the Comparable Suggests

Neo’s management raised full-year 2026 EBITDA guidance to USD 100 to 110 million following the Q1 2026 results, which themselves came in at USD 36.2 million, more than double the same quarter one year prior. At a USD 105 million EBITDA midpoint for 2026, Neo trades at approximately 9 times forward EBITDA on its current market cap of approximately USD 880 million.

This multiple is not appropriate for this business. Here is why.

The peer group comparison in Part 3 showed that MP Materials, which only turned its first meaningful positive adjusted EBITDA quarter in Q1 2026, commands a USD 9.8 billion market cap, and that Lynas trades at roughly 50 times its own EBITDA. These are outliers inflated by narrative premium and scarcity of investable Western rare earth equities. I don’t think Neo deserves a 50x multiple. The Magnequench business has commodity exposure, the C&O segment has structural headwinds in European automotive catalysts, and the Rare Metals segment is inherently lumpy. These are real constraints.

But Stifel’s May 2026 analysis noted that the advanced materials comparable group, companies with similar downstream processing characteristics, specialty chemicals and functional materials businesses, trades at 16.5 times EV/EBITDA. This is the right reference point, not the mining or upstream extraction peers. Neo is not a miner. It is a manufacturer of high-specification functional materials with 40 years of customer relationships and the only Western European sintered magnet plant in commercial operation. At 16.5 times 2026E EBITDA of USD 105 million, the implied enterprise value is approximately USD 1.73 billion. Neo held a net cash position at year-end 2025, approximately USD 85 million in cash against USD 65 million in total debt including the USD 50 million EDC term loan, implying net cash of roughly USD 20 million. Adding that to the implied EV, the implied market cap is approximately USD 1.75 billion; approximately 99% above the current USD 880 million. In Canadian dollar terms, that implies a share price of approximately CAD 57, against the current CAD 28.70.

At 20 times, a modest premium to the advanced materials group that reflects the strategic scarcity of Neo’s position as sole Western EU-based magnet manufacturer - the implied market cap reaches approximately USD 2.12 billion, or approximately CAD 69 per share. A 140% premium to current price.

I think 16.5 times is the right multiple. Not because it is conservative, but because it is defensible. The business deserves to trade in line with functional materials peers. It currently trades at a 46% discount to that group. The discount has a name: it is the TSX listing, the Canadian dollar denomination, and the three-segment P&L that makes the core business invisible to the European and American analysts who cover the sector. When one of those three things changes, a listing upgrade, a large strategic investor, or a period of sustained earnings momentum that forces coverage, the discount compresses. The thesis does not require a rerating event to be correct. It requires the market to eventually read the right number.

---

Catalyst Timeline

2025 (completed): The Narva plant opened on schedule and on budget in September 2025. The Bosch MOU was signed simultaneously. The heavy rare earth separation (HREE) line at Sillamäe was installed. Full-year EBITDA of USD 75.6 million exceeded guidance. These are not speculative. They happened. The question is why the stock traded below CAD 10 as recently as March 2024 and has only partially re-rated to the current CAD 28.70 despite an executed strategic programme.
Catalyst strength: 7/10 (already occurred, partial re-rating complete).

Q2-Q4 2026: Narva ramp toward the 2,000-tonne Phase 1A capacity ceiling. Each incremental tonne of sintered magnet production carries higher margins than the legacy bonded powder business and is additive to a group EBITDA baseline that has already been reset upward. Management’s USD 100 to 110 million guidance already embeds a conservative assumption about Narva’s contribution. If traction motor qualifications convert to volume orders from European Tier 1 customers faster than management modelled, the 2026 number could again beat guidance. This is the highest-probability catalyst in the near term. Catalyst strength: 8/10.

2026-2027: CRMA Strategic Project designation for Phase 1B expansion at Narva (5,000+ tonnes per year). The second call for CRMA strategic projects closes in early 2026 with decisions expected in mid-2026. If Narva Phase 1B is selected, and given that it is the only EU-origin sintered magnet facility in operation, the strategic fit is unambiguous, it would unlock streamlined permitting, preferred access to public financing, and potentially additional EU grant support. The combination of grant funding, EDC-style debt financing, and a Bosch-anchored customer base would make Phase 1B a fundable expansion without material equity dilution. This would add approximately 150% to Neo’s European sintered magnet capacity and position it ahead of any credible new entrant for the next decade. Catalyst strength: 7/10.

2027-2028: Humanoid robot demand for bonded NdFeB powder begins appearing in Magnequench volume data. At Goldman Sachs’ 250,000 humanoid unit base case for 2030, and at 1.3 kilograms of NdPr content per unit, the humanoid contribution to bonded powder demand represents a meaningful incremental volume layer on top of the EV and wind turbine base. Magnequench is the only Western supplier qualified to serve this market. The demand does not arrive all at once, it ramps with robot production, but by 2027 the volume signals should be visible in quarterly earnings. The re-rating from “EV supplier” to “humanoid robot critical supplier” is, in the current narrative environment, not a trivial event. Catalyst strength: 6/10 (meaningful but timing uncertain).

---

The Risks

There are three risks that deserve honest treatment, not because they are likely to materialise, but because they are real and any investment decision should account for them.

The first is Narva ramp risk. The Narva plant is operational and shipping qualification samples, but converting samples to volume orders is not automatic. Automotive qualification processes fail. They get delayed. They get restructured when an OEM changes platform architecture mid-cycle. If the traction motor qualifications currently underway do not convert to volume by 2027, the incremental EBITDA contribution from Narva will be smaller than the thesis assumes and the Phase 1B case weakens.
Financial impact: a 2-year delay in full Narva utilisation would reduce cumulative 2026-2028 EBITDA by an estimated USD 50 to 80 million relative to the optimistic scenario, implying a fair value closer to USD 1.3 billion than USD 1.7 billion at 16.5 times. This risk is real. It does not break the thesis. It changes the timeline.

The second is Rare Metals pricing normalisation. Q1 2026 Rare Metals EBITDA of USD 23.9 million was driven partly by rare earth and rare metal price spikes triggered by Chinese export controls. These price spikes are not permanent. When China’s export licensing regime stabilises, as it did after the 2010 export quota crisis, which ultimately resolved within 18 to 24 months; pricing will partially normalise. Management’s USD 100 to 110 million full-year 2026 guidance already builds in some normalisation assumption, but the actual path of Chinese export policy is not predictable. If rare earth prices revert sharply toward 2024 lows before Narva’s volume ramp offsets the Rare Metals decline, group EBITDA could undershoot guidance. Financial impact: a 30% decline in Rare Metals EBITDA from the annualised Q1 2026 run rate would reduce full-year group EBITDA by approximately USD 25 to 30 million relative to the raised guidance midpoint. Not fatal, but meaningful for the valuation.

The third risk is the TSX listing premium, or rather, the discount. This is a structural risk that could persist longer than the thesis needs it to. Neo’s listing on a Canadian exchange in Canadian dollars means it is invisible to the majority of institutional capital that covers the rare earth and advanced materials space. An exchange listing or a dual-listing in the US or Europe would materially accelerate the re-rating. Management is aware of this. Whether it happens on a timeline that matters for a 2-to-3-year investment horizon is not known. If no listing event occurs, the valuation gap may persist even as earnings grow, simply because the right audience never sees the stock. This is not a business risk. It is a market structure risk. None of these are fatal. They are real.

---

The Thesis

Neo Performance Materials is the only company in the Western world operating commercial-scale NdFeB magnetic powder production and an operational sintered magnet facility in Europe simultaneously. Its 40-year Magnequench IP lineage is the result of General Motors Pentagon-funded research that cannot be recreated by acquisition or licensing. Its Narva plant is the first and only EU-origin sintered magnet facility, fully funded, operational, and already engaged in automotive platform qualifications with Bosch as the anchor customer. Its EBITDA grew 103% over two years on a flat revenue base. Its 2026 EBITDA guidance, raised after a record Q1 beat that exceeded consensus EPS by approximately 95%, sits at USD 100 to 110 million. It trades at approximately 9 times that guidance, while peers without its downstream position command market caps ten to fourteen times larger.

At 16.5 times 2026 EBITDA, a multiple in line with the advanced materials comparable group, and a discount to every company in the rare earth sector the implied market cap is approximately USD 1.75 billion, representing roughly 99% upside from the current USD 880 million. At current prices, this is a 2-to-3-year thesis. If you wait until everyone knows, it’s too late.

The entry price today is approximately USD 20.85 per share (CAD 28.70 at current rates). The thesis does not require a perfect entry. It requires that the market eventually reads EBITDA instead of revenue, that Narva converts qualifications to volume, and that at least one of the catalyst events - CRMA Phase 1B, humanoid powder demand, listing upgrade and closes the coverage gap. At 16.5 times forward EBITDA on a business this strategically positioned, the implied fair value is approximately CAD 57 per share. The margin of safety is built into the multiple, not the timing.

This is not a trade. It is a position.

---

This article is for informational purposes only and reflects my personal opinion and analysis. I am not a financial advisor. Nothing written here constitutes financial advice.

Always do your own research (DYOR) before making any investment decision.

I hold a position in NEO (TSX: NEO). Given the thesis outlined above, that is likely to increase even more.